Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

My previous session
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular and Member of the Executive Committee

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 10:30am CEST

Release date- 04102017 - Paris, France - Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effective immediately.

In this role, Mr. Oelrich will be a member of the Executive Committee.

'Stefan is a highly effective leader who has demonstrated his ability to deliver strong results during his tenure at Sanofi,' said Olivier Brandicourt, Sanofi's Chief Executive Officer. 'As one of the architects of our Diabetes & Cardiovascular business unit, I am confident Stefan will succeed in driving our strategy forward in the coming years.'

Mr. Oelrich has served as head of Sanofi's global diabetes franchise since June 2016 and as acting head of the DCV North America business since July. He will continue to lead both functions ad interim until successors are named.

He previously served as DCV Europe Region Head & Sanofi Europe Coordinator, and was heavily involved in establishing the DCV global business unit since mid-2015. Between 2011 and 2015 he served as General Manager in Germany, Switzerland and Austria.

Mr. Oelrich began his career in Bayer AG in Germany in 1992 where he held positions of increasing responsibility and leadership across Latin America, Europe and the US including General Manager for Bayer Healthcare in Belgium and in France. He led Bayer Pharmaceutical's US Marketing as VP of Marketing followed by a promotion to SVP & General Manager US Women's Healthcare.

A citizen of Germany, Mr. Oelrich holds a Master's degree in Business Administration from the Business School of the Cologne Chamber of Commerce.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


Jack Cox

Tel: +33 (0)1 53 77 46 46

Email: mr@sanofi.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
02:25pSANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
08/16Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Prov..
08/16THERAPEUTIC VACCINES MARKET 2018 : Global Industry Future Analysis & Growth by T..
08/16POMPE DISEASE MARKET IS GROWING AT A : Pompe Disease Market – Global Indus..
08/15SANOFI : The Top 50 Generic Drug Producers Had Combined Revenues of $92bn in 201..
08/13SANOFI : Disclosure of trading in own shares
08/11SANOFI : Early Phase Results Promising for BTK Inhibitor in Multiple Sclerosis T..
08/10SANOFI : Polluting Sanofi factory allowed to partially resume manufacturing
08/09SANOFI : Recent Studies from Sanofi Pasteur Add New Data to Hepatitis (Host cell..
08/09SANOFI : Study Findings on Eye Proteins Are Outlined in Reports from Sanofi (Com..
More news
News from SeekingAlpha
08/15Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q2 2018 Update 
08/14Eton Pharmaceuticals Files For U.S. IPO 
08/13Amicus Receives First FDA Approval For Fabry Disease Treatment In 15 Years 
08/13Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare D.. 
08/10Premarket analyst action - healthcare 
At a Crossroads
Financials (€)
Sales 2018 35 025 M
EBIT 2018 8 524 M
Net income 2018 5 102 M
Debt 2018 16 254 M
Yield 2018 4,23%
P/E ratio 2018 17,61
P/E ratio 2019 16,52
EV / Sales 2018 3,04x
EV / Sales 2019 2,94x
Capitalization 90 311 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 79,6 €
Spread / Average Target 9,6%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI1.13%102 916
JOHNSON & JOHNSON-5.18%347 417
PFIZER14.36%238 136
NOVARTIS-0.83%207 488
ROCHE HOLDING LTD.-2.96%206 696
MERCK AND COMPANY22.36%176 752